Universal Beteiligungs und Servicegesellschaft mbH Has $4.60 Million Position in Alkermes plc (NASDAQ:ALKS)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Alkermes plc by 22.4%, owning approximately 0.08% of the company worth $4.6 million as of its latest SEC filing.
• Several institutional investors have made significant adjustments to their holdings in Alkermes, with JPMorgan Chase & Co. raising its position by 147.4% during the fourth quarter.
• Alkermes recently reported earnings of $0.13 per share, missing the consensus estimate of $0.32, with a decline in revenue compared to the previous year.

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 22.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,311 shares of the company's stock after purchasing an additional 25,493 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of Alkermes worth $4,600,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ALKS. RTW Investments LP grew its stake in Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock worth $217,363,000 after buying an additional 903,802 shares during the last quarter. Renaissance Technologies LLC grew its stake in Alkermes by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after buying an additional 57,697 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Alkermes by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after buying an additional 128,701 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in Alkermes during the 4th quarter worth $70,462,000. Finally, Norges Bank bought a new position in Alkermes during the 4th quarter worth $56,684,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ALKS. HC Wainwright restated a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a research note on Monday, July 21st. UBS Group raised Alkermes from a "neutral" rating to a "buy" rating and upped their target price for the company from $33.00 to $42.00 in a report on Tuesday, June 17th. Robert W. Baird upped their target price on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. The Goldman Sachs Group began coverage on Alkermes in a research report on Tuesday, July 15th. They set a "buy" rating and a $43.00 price target on the stock. Finally, Cantor Fitzgerald raised Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.08.

Insider Activity at Alkermes

In other news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the completion of the sale, the senior vice president directly owned 86,208 shares of the company's stock, valued at approximately $2,680,206.72. This trade represents a 3.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.40% of the company's stock.

Alkermes Stock Down 3.4%

Shares of ALKS stock traded down $0.95 during mid-day trading on Thursday, reaching $26.98. The stock had a trading volume of 605,490 shares, compared to its average volume of 1,792,653. The firm's 50 day simple moving average is $29.34 and its 200 day simple moving average is $30.79. Alkermes plc has a one year low of $25.56 and a one year high of $36.45. The firm has a market cap of $4.45 billion, a PE ratio of 12.98, a P/E/G ratio of 1.65 and a beta of 0.44.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.42 by $0.10. The business had revenue of $390.66 million during the quarter, compared to the consensus estimate of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%. Alkermes's revenue was down 2.1% on a year-over-year basis. During the same quarter last year, the company earned $1.16 EPS. Sell-side analysts forecast that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.